Peginterferon alfa-2a - Rhein Minapharm Biogenetics

Drug Profile

Peginterferon alfa-2a - Rhein Minapharm Biogenetics

Alternative Names: Hansenula-derived peginterferon alpha-2a; PEG-IFN alpha-2a - Rhein Minapharm Biogenetics; PEG-interferon alpha-2a - Rhein Minapharm Biogenetics; Peginterferon alpha-2a - Rhein Minapharm Biogenetics; Reiferon Retard

Latest Information Update: 21 Feb 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rhein Minapharm Biogenetics
  • Class Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Jan 2005 Launched for Hepatitis C in Egypt (SC)
  • 28 Dec 2004 Registered for Hepatitis C in Egypt (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top